(2020) Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy? Archives of Medical Research. pp. 733-735. ISSN 0188-4409
![[img]](http://eprints.bmsu.ac.ir/style/images/fileicons/text.png) |
Text
Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy.pdf Download (441kB) |
Abstract
The discovery of new drugs for treating the new coronavirus (SARS-CoV-2) or repurposing those already in use for other viral infections is possible through understanding of the viral replication cycle and pathogenicity. This article highlights the advantage of targeting one of the non-structural proteins, helicase (nsp13), over other SARS-CoV-2 proteins. Highlighting the experience gained from targeting Nsp13 in similar coronaviruses (SARS-CoV and MERS) and known inhibitors, the article calls for research on helicase inhibitors as potential COVID-19 therapy. (C) 2020 IMSS. Published by Elsevier Inc.
| Item Type: | Article |
|---|---|
| Keywords: | COVID-19 Helicase SARS-CoV-2 Research & Experimental Medicine |
| Page Range: | pp. 733-735 |
| Journal or Publication Title: | Archives of Medical Research |
| Journal Index: | ISI |
| Volume: | 51 |
| Number: | 7 |
| Identification Number: | https://doi.org/10.1016/j.arcmed.2020.05.024 |
| ISSN: | 0188-4409 |
| Depositing User: | مهندس مهدی شریفی |
| URI: | http://eprints.bmsu.ac.ir/id/eprint/8555 |
Actions (login required)
 |
View Item |